Table 1.

Clinical characteristics of enrolled subjects.

	NC(n=49)	HBV-LC(n=31)	HBV-HCC(n=26)	p
Gender (male/female)	27/22	19/12	22/4*	0.037
Age (year)	52.14 ± 12.73	50.90 ± 10.24	53.31 ± 10.05	0.173
AFP (<400/≥400 ng/ml)	NA	NA	17/9
HBV-DNA (<100/≥100IU/ml)	NA	10/21	9/17	1.000
HBeAg (-/+)	49/0	24/7*	18/8*	<0.0001
WBC (*109/L)	5.94 ± 1.61	4.52 ± 2.45*	6.54 ± 3.67	0.013
RBC (*1012/L)	4.50 ± 0.41	3.86 ± 0.77*	3.94 ± 0.89*	<0.0001
Hb (g/L)	134.57 ± 12.17	110.77 ± 23.67*	118.42 ± 27.10*	<0.0001
PLT (*109/L)	218.94 ± 52.52	97.03 ± 55.89*	136.42 ± 90.00*	<0.0001
PT (s)	13.18 ± 0.64	17.35 ± 3.57*	16.34 ± 3.41*	<0.0001
INR	0.99 ± 0.06	1.40 ± 0.37*	1.30 ± 0.35*	<0.0001
ALT (U/L)	23.84 ± 20.62	81.03 ± 116.20*	79.92 ± 93.27*	0.003
AST (U/L)	21.47 ± 7.71	73.97 ± 65.62*	145.65 ± 206.88*	<0.0001
TBIL (umol/L)	10.86 ± 3.70	53.63 ± 103.01	46.47 ± 68.61*	0.005
ALB (g/L)	42.08 ± 3.23	34.34 ± 5.24*	33.81 ± 6.18*	<0.0001
BCLC stage (A/B/C/D)	NA	NA	8/2/10/6

NC, normal controls; HBV-LC, hepatitis B virus-related liver cirrhosis; HBV-HCC, Hepatitis B virus-associated hepatocellular carcinoma; AFP, Alpha-fetoprotein; HBeAg, hepatitis B e antigen; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; PLT, platelet; PT, prothrombin time; INR, International normalized ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; ALB, Albumin; BCLC, Barcelona Clinic Liver Cancer; NA, not applicable.

*p value < 0.05 vs normal controls.